BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 17, 2010
View Archived Issues
Pharma Outlicensing: From Opportunism to R&D Funding
A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying.
Read More
Money Raised Year to Date
Read More
Savient for Sale, Ardea Bid Adds Dose: Gout on Move
Read More
German Plan: Blood in Water for Overseas Reimbursement?
Read More
Money Raised By Biotech in 2010
Read More
Week in Review
Read More
Word on the Street
Read More
FDA Approvals in April
Read More
Phase I Clinical Trials Update: April 2010
Read More
Phase II Clinical Trials Update: April 2010
Read More
Pivotal/Phase III Clinical Trials Update: April 2010
Read More
Non-U.S. Clinical Trials And Regulatory Actions: April 2010
Read More
FDA Submissions, Approvals And Other Actions: April 2010
Read More
Stock Gainers and Losers For The Week
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More